1. Wolfe F, Smythe HA, Yunus MB; et al, Report of the Multicenter Criteria
Committee. The American College of Rheumatology 1990 Criteria for the
Classification of Fibromyalgia. Arthritis Rheum. 1990;33(2):160-172.
2. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and
characteristics of fibromyalgia in the general population. Arthritis Rheum.
Jan 1995;38(1):19-28.
3. Häuser W, Bernardy K, Üçeyler N, Sommer C. Treatment of Fibromyalgia
Syndrome With Antidepressants: A Meta-analysis. JAMA. 2009;301(2):198-
209.
4. Uçeyler N, Häuser W, Sommer C. A systematic review on the effectiveness
of treatment with antidepressants in fibromyalgia syndrome. Arthritis
Rheum (2008) 59:1279–98.
5. Staud R. Evidence of involvement of central neural mechanisms in
generating fibromyalgia pain [review]. Curr Rheumatol Rep 2002; 4:299–
305.
6. Bennett RM. Emerging concepts in the neurobiology of chronic pain:
evidence of abnormal sensory processing in fibromyalgia [review]. Mayo
Clin Proc 1999;74:385–98.
7. Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in
fibromyalgia. Clin J Pain 1997;13:189–96.
8. Pillemer SR, Bradley LA, Crofford LJ, Moldofsky H, Chrousos GP.
The neuroscience and endocrinology of fibromyalgia. Arthritis Rheum
1997;40:1928–39.
9. Rowbotham MC. Is fibromyalgia a neuropathic pain syndrome? [review]. J
Rheumatol Suppl 2005;75:38–40.
10. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin
AE, Young JP Jr, LaMoreaux LK, Martin SA, Sharma U; Pregabalin 1008-
105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome:
results of a randomized, double-blind, placebo-controlled trial. Arthritis
Rheum. 2005 Apr;52(4):1264-73.
11. Arnold LM, Russel IJ, Diri EW, et al. A 14-week, randomized, doubleblind, placebo-controlled, monotherapy trial of pregabalin in patients with
fibromyalgia. J Pain. 2008;9(9):792–805.
12. Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment
of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter
trial. Arthritis Rheum. 2007;56:1336-1344.
13. Beck AT, Waed CH, Mendelson M. An inventory for measuring depression.
Arch Gen Psychiatry 1961; 4:561-571
14. Hisli N. Beck Depresyon Ölçeği’nin bir Türk örnekleminde geçerlik ve
güvenirliği. Psikoloji Dergisi 1988; 6:118-122
15. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact
Questionnaire: development and validation. J Rheumatol 1991;18:728-733
16. Sarmer S, Ergin S, Yavuzer G. The validity and reliability of the Turkish
version of the Fibromyalgia Impact Questionnaire. Rheumatol Int 2000;
20:9-12
17. Ataoğlu S, Ataoğlu A, Erdoğan F, Saraç J. Comparison of paroxetine,
amitriptyline in the treatment of fibromyalgia. Turk J Med Sci. 1997;27:535-
539.
18. Çapaci K, Hepgüler S. Comparison of the effect of amitriptyline and
paroxetine in the treatment of fibromyalgia syndrome. Pain Clin.
2002;14:223-228.
19. Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A,McGuire H,
Churchill R, Barbui C. Escitalopram versus other antidepressive agents for
depression. Cochrane Database Syst Rev 2009: CD006532.
20. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JPT, Churchill
R, et al. Comparative efficacy and acceptability of 12 new-generation
antidepressants: a multiple-treatments metaanalysis. Lancet 2009; 373:
746-758.
21. Hoschl C, Svestka J. Escitalopram for the treatment of major depression
and anxiety disorders. Expert Rev Neurother 2008; 8:537-552.
22. Wu E, Greenberg PE, Yang E, Yu A, Erder MH.Comparison of escitalopram
versus citalopram for the treatment of major depressive disorder in a
geriatric population. Curr Med Res Opin. 2008 Sep;24(9):2587-95. Epub
2008 Jul 31.
23. Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ,
Agibalova TV.Efficacy and tolerability of escitalopram versus citalopram in
major depressive disorder: a 6-week, multicenter, prospective, randomized,
double-blind, active-controlled study in adult outpatients. Clin Ther. 2007
Nov;29(11):2319-32.
24. Mazzaa M, Mazzab O, Pomponia M, Di Nicolaa M, Paduac L, Vicinib M,
Briaa P and Mazzac S. What is the effect of selective serotonin reuptake
inhibitors on temperament and character in patients with fibromyalgia?
Comprehensive Psychiatry Volume 50, Issue 3, May-June 2009, Pages
240-244
25. Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with
fibromyalgia: a randomized, double-blind,placebo-controlled study. Eur J
Pain 2000;4:27–35.
26. Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized
controlled trial of citalopram in the treatment of fibromyalgia. Pain
1995;61:445–9.
27. Pan HL, Eisenach JC, Chen SR. Gabapentin suppresses ectopic nerve
discharges and reverses allodynia in neuropathic rats. J Pharmacol Exp
Ther 1999;288:1026–30.
28. Hao JX, Xu XJ, Urban L, Wiesenfeld-Hallin Z. Repeated administration of
systemic gabapentin alleviates allodynia-like behaviors in spinally injured
rats. Neurosci Lett 2000;280:211–4.
29. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M,
et al. Gabapentin for the symptomatic treatment of painful neuropathy
in patients with diabetes mellitus: a randomized controlled trial. JAMA
1998;280:1831–6.
30. Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in
neuropathic pain states.Clin J Pain 1996; 12: 56-8.
31. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L.
Gabapentin for the treatment of postherpetic neuralgia: a randomized
controlled trial. JAMA 1998;280:1837–42.
32. Rice AS, Maton S, Postherpetic Neuralgia Study Group. Gabapentin in
postherpetic neuralgia: a randomised, double blind, placebo controlled
study. Pain 2001;94:215–24.
33. Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, et al.
Efficacy of gabapentin in migraine prophylaxis. Headache 2001;41:119–28.
34. Gore M, Sadosky AB, Zlateva G, Clauw DJ.Clinical characteristics,
pharmacotherapy and healthcare resource use among patients with
fibromyalgia newly prescribed gabapentin or pregabalin. Pain Pract. 2009
Sep-Oct;9(5):363-74.
Thank you for copying data from http://www.arastirmax.com
